The aim of this study was to investigate the relation between bladder cancer risk and the use of selected drugs for cardiovascular disease (CVD) prevention, such as aspirin, statins, and calcium channel blockers (CCBs). We analyzed data from a multicentric case-control study carried out in Italy between 2003 and 2014, including 690 bladder cancer cases and 665 hospital controls. Odds ratios (ORs) of bladder cancer and corresponding 95% confidence intervals (CIs) were estimated using unconditional multiple logistic regression models. The ORs for bladder cancer were 1.21 (95% CI: 0.87-1.68) for regular use of aspirin, 0.72 (95% CI: 0.54-0.97) for use of any CCBs, and 1.32 (95% CI: 0.87-1.99) for use of any statins. A slight inverse association was found with duration of use of CCBs, whereas no consistent association was found with duration of use, age at first use, and frequency for aspirin and statin use, or with indication of use for aspirin (as an analgesic or, for CVD prevention). No significant association was found for various combinations of drugs or for all drugs combined (OR = 1.23, 95% CI: 0.31-4.85). Our data indicate the lack of a relevant association between the use of selected drugs for CVD prevention and bladder cancer risk, although suggest a potential favorable role for CCBs. European Journal of Cancer Prevention 28:76-80
Introduction
With the progressive aging of the population, drugs for primary prevention of cardiovascular disease (CVD) are increasingly being prescribed. These include mostly antihypertensives, aspirin, and statins, frequently used in association. However, their action on carcinogenesis, particularly on the bladder, is not fully understood when used alone or in various combinations. Aspirin use, because of its anti-inflammatory properties, has been inversely related to the risk of various common cancers, including those of the colorectum, esophagus, stomach, breast, and prostate (Bosetti et al., 2012b; Cuzick et al., 2015) . Statins have anticancer activities in 'in-vivo ' and 'in-vitro' studies (Coogan et al., 2007) , and meta-analyses of epidemiological studies showed significant reductions of hematological malignancies (Yi et al., 2014) and prostate cancer , and a nonsignificant decreased risk of lung (Wang et al., 2013) , breast , and kidney (Zhang et al., 2014) cancers. However, a recent combined analysis of randomized trials showed no material effect of statin on cancer risk (Collins et al., 2016) . Only a few studies have been carried out on the association between antihypertensive agents and cancer risk. Current use of any antihypertensive agents, such as angiotensin-converting enzyme inhibitors, β-blockers, and calcium channel blockers (CCBs), has been associated with a higher risk of breast cancer, with no relation with duration (Chang et al., 2016) .
Specifically for bladder cancer risk, several epidemiological studies have considered the relation with aspirin with however inconsistent results, ranging from null (Daugherty et al., 2011; Baris et al., 2013) , to direct (Ratnasinghe et al., 2004) or inverse (Castelao et al., 2000) associations. Two recent meta-analyses pooling such results found an overall null association (Bosetti et al., 2012a; Zhang et al., 2013a) . Two other meta-analyses on statin use and bladder cancer risk indicated no increased risk among users (Zhang et al., 2013b; Luo et al., 2015) . The relation between any antihypertensive agents and bladder cancer risk was investigated in an US population case-control study reporting null results (Jiang et al., 2010) .
As control and prevention of CVD generally involves the use of multiple drugs, drug interactions should also be considered. Particularly, statins are metabolized by the cytochrome P450 3A4 into more water-soluble metabolites excreted in either bile or urine. Drugs inhibiting cytochrome P450 3A4 activity, such as CCBs (verapamil, diltiazem, and mibefradil), might increase plasma statin levels.
The aim of this paper is to present further data on the association between the use of selected drugs for CVD prevention and bladder cancer risk, using data from a case-control study carried out in Italy between 2003 and 2014.
Patients and methods
A case-control study on bladder cancer was carried out between 2003 and 2014 within an established Italian network of collaborating centers, including Aviano (Pordenone) and Milan in northern Italy, and Naples and Catania in southern Italy (Polesel et al., 2014; Turati et al., 2015) . Cases were 690 patients (595 men and 95 women, median age 67 years; range: 25-84 years) with incident transitional cell carcinoma of the bladder admitted to major general hospitals in the study areas. Nearly all bladder cancers were confirmed by histological testing on tumor tissue specimen from biopsy or surgery, and three cases were confirmed by cytology only. Controls were patients admitted to the same hospitals as cases for a wide spectrum of acute, non-neoplastic conditions, not related to smoking or other known or likely risk factors for bladder cancer. The control group included 690 patients frequency matched to cases by study center, sex, and 5-year age group. Twenty-five controls were excluded after enrollment because of inappropriate admission diagnosis, thus leaving 665 eligible controls (561 men and 104 women; median age 66 years; range: 27-84 years). Overall, 28.9% of controls were admitted for traumas, 22.1% for nontraumatic orthopedic disorders, 39.3% for acute surgical conditions, and 9.8% for miscellaneous other illnesses. All study participants signed an informed consent according to the recommendations of the Board of Ethics of the study hospitals. The proportion of refusal among cases and controls approached was less than 5%.
All participants were interviewed during their hospital stay using a structured questionnaire including information on sociodemographic characteristics, anthropometric measures, selected lifestyle and dietary habits (including tobacco smoking and alcohol drinking), a personal history of selected diseases and drug use, and family history of cancer. Information on the use of aspirin, CCBs, and statins included age at first use, frequency, and duration of use. Indication for use of aspirin (i.e. analgesic or CVD prevention) was also recorded. Regular use was defined as use for at least once a week for more than 6 months. Comprehensive lists of the main preparations in Italy containing aspirin (any medication containing acetylsalicylic acid), CCBs, or statins were supplied to facilitate recall.
Odds ratios (OR) of bladder cancer and the corresponding 95% confidence intervals (CIs) according to the use of aspirin, CCBs, and statins were estimated using unconditional multiple logistic regression models adjusted for age, sex, study center, year of interview, education, tobacco smoking, and diabetes. Additional models including further terms for alcohol consumption, body mass index, family history of bladder cancer, and history of cystitis did not markedly alter the OR, and therefore these covariates were not included in the final models. ORs of bladder cancer for the use of various combinations of the three classes of medications were also estimated.
Results Table 1 presents the distribution of bladder cancer cases and controls according to selected variables. By design, cases and controls had a similar distribution by study center, sex, and age. The two groups were also similar in terms of education, whereas current and heavy tobacco smoking and the history of diabetes were more frequent among cases than controls. For aspirin use, no association was also found for high cumulative doses in a Spanish case-control study (Fortuny et al., 2006) , for dose in a New England case-control study (Baris et al., 2013) , for long duration of use (>11 years) in the same study and in the American Cancer Society-Cancer Prevention Study II (ACS-CPS II). Cohort (≥5 years) (Jacobs et al., 2007) , and for dose and frequency of use in the the Health Professionals Follow-Up Study (Genkinger et al., 2007) . Moreover, a large-scale, long-term trial based on data from the Women's Health Study showed that low-dose aspirin use (100 mg/day) for an average 10 years did not reduce the incidence of bladder cancer (Cook et al., 2005) . Thus, overall evidence indicates a lack of role of aspirin in bladder carcinogenesis.
The relation between long-term statin use (mostly > 5 years) and bladder cancer was considered in several randomized clinical trials, cohort, and case-control studies, finding mixed results. A meta-analysis of these studies reported an overall relative risk of 1.21 (95% CI: 0.92-1.59) (Zhang et al., 2013b) . Thus, although a few studies (Sato et al., 2006; Friedman et al., 2008; Vinogradova et al., 2011) , including ours, found a slightly increased risk, overall, no association emerged, and the issue needs to be investigated further.
To our knowledge, this is the first epidemiological study evaluating the relation between the risk of bladder cancer in CCB users and in users of various combinations of aspirin, statins, and CCBs. The inverse association with the dose and duration of CCB use suggests a real favorable effect on bladder cancer risk. Preclinical studies in vitro and in vivo have indicated that CCBs may be effective in blocking abnormal cell proliferation in several tumors (Mason, 1999) . In any case, the protective effect of CCB use and bladder cancer in humans needs further investigation.
Although based on a relatively large sample size, our study included a small proportion of regular drug users according to the reported pattern of aspirin use in Italy (Lugo et al., 2014) . Moreover, we had no information on the type of medication and the doses. Another possible limitation of our study is selection bias. However, cases and controls were from comparable catchment areas, and the participation rate was almost complete. In addition, some of the diagnostic categories of the controls may be associated with increased drug use, mainly, aspirin and/or other analgesics. However, the risk estimates did not change across the major diagnostic categories of controls, and patients admitted to hospital for CVD and diseases related to smoking were excluded from the control group. As for recall bias, hospital controls are preferable with reference to the reliability and validity of information on drug use, as they are similarly sensitized toward various aspects of their medical history (Bosetti et al., 2001) . Major confounding is also unlikely, because the risk estimates were adjusted for major risk factors of bladder cancer, including detailed information on smoking, and further adjustment for many other variables did not modify the risk estimates.
Conclusion
Our findings, although based on few regular users of the selected drugs, are reassuring, suggesting a lack of relationship of aspirin and statins and a potential favorable effect of CCBs used for CVD prevention and bladder cancer risk.
